Product Pipeline
At Acytronix, we are pioneering the next generation of biological purification methods, with ambitious plans for future expansions into diagnostics, liquid biopsy, and drug delivery. Our advanced PMED (Portable Microstructured Electrochemical Device) technology is at the heart of our product development, setting new standards in the biotechnology industry.
Biological Nanoparticles Purification
Our flagship product, focusing on the purification of extracellular vesicles, is set to revolutionize the biological nanoparticles market. Valued at $4.7 billion and growing at a CAGR of 29.9%, this sector is poised for rapid expansion. Acytronix's PMED technology ensures unparalleled precision and efficiency in nanoparticle purification, catering to the high demand for purity in biopharmaceutical applications.
Automated EV-Based Therapeutic Personalization System
Our novel technology aims to advance personalized medicine and proteomics analysis. This system involves collecting extracellular vesicles from patients using our PMED technology. The extracellular vesicles undergo proteomic profiling through data-independent analysis (DIA) to identify key proteins. Based on these proteomic profiles, artificial intelligence (AI)-based therapeutic procedures are advised to address abnormalities and personalize treatments. The treatment is administered automatically, with real-time monitoring and a feedback loop to optimize efficacy. Integration with Electronic Health Records (EHR) ensures a seamless clinical workflow. This system promises personalized treatment, improved healing and recovery, and scalability to other medical conditions like cancer and metabolic disorders, significantly advancing personalized medicine.
Liquid Biopsy
Blood-based test for Parkinson’s disease detection and treatment monitoring. Acytronix is advancing into the liquid biopsy market, focusing on research and development of blood-based diagnostics and treatment monitoring for Parkinson’s disease and other neurological disorders. This market, projected to reach $5 billion with a 7% CAGR, will benefit from our PMED technology's precision in detecting neurodegeneration biomarkers. Our solution aims to provide non-invasive, real-time monitoring of disease progression and treatment response, improving patient outcomes and treatment strategies
About Acytronix
Acytronix is committed to driving innovation in biotechnology. Our state-of-the-art PMED technology is the cornerstone of our product pipeline, delivering unprecedented precision and efficiency in biological purification and molecular delivery. We are dedicated to transforming scientific advancements into real-world applications, improving lives and setting new industry standards.Our vision extends beyond current market offerings, as we continuously explore new frontiers in diagnostics, therapeutics, and regenerative medicine. Acytronix's commitment to excellence and innovation positions us as a leader in the biotechnology sector, ready to meet the challenges of tomorrow.